People with hypertrophic cardiomyopathy combined with atrial fibrillation may be treated with medications such as anticoagulants, beta-blockers, or catheter ablation, depending on their condition. Hypertrophic cardiomyopathy (HCM) is a cardiac muscle disease characterized by myocardial hypertrophy. The incidence of atrial fibrillation in patients with hypertrophic cardiomyopathy is much higher than that in the general population, and about 20-25% of patients with hypertrophic cardiomyopathy suffer from concomitant atrial fibrillation, which is the main reason for the deterioration of clinical symptoms of hypertrophic cardiomyopathy. Amiodarone is the most effective drug to terminate paroxysmal atrial fibrillation and to prevent recurrence, and the combined use of propyzamide and β-blockers has the effect of decreasing the pressure gradient of the left ventricular outflow tract, and for chronic atrial fibrillation, verapamil and β-blockers are often used to control the ventricular rate. In addition, oral anticoagulants such as warfarin should be used to prevent thromboembolism in patients with hypertrophic cardiomyopathy combined with paroxysmal, persistent, or permanent atrial fibrillation, as long as they are not contraindicated. For some patients with permanent atrial fibrillation, atrioventricular node catheter ablation and implantation of a permanent ventricular pacemaker can be considered. Catheter ablation has a resuscitation success rate of about 67% in patients who are difficult to reset the rhythm after treatment with various antiarrhythmic drugs, such as amiodarone, and has a certain effect on the enhancement of cardiac function in the three years after the procedure. People with hypertrophic cardiomyopathy complicated by atrial fibrillation should go to the hospital and take targeted therapeutic measures under the guidance of the doctor and in accordance with medical advice.